Langer-backed Kala scores $90M IPO as it lines up a pair of NDAs
Kala Pharmaceuticals has now joined the ranks of this year’s biotech IPO class, hitting the range and raising $90 million after pricing shares at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
